We have tested the Transplant Monitoring System assay manufactured by GTI to detect specifi cally HLA class I (class I-Ab) or class II antibodies (class II-Ab) by ELISA crossmatch (ELISA-CM) method. Human sera with class I-Ab (n=68), with class II-Ab (n=50), without class I-Ab (n=32) and without class II-Ab (n=9), were tested to HLA glycoproteins prepared from HLA-typed donor's spleen cells (n=20) by lysing frozen packed spleen cells with a detergent. HLA class I-Ab were identifi ed into recipient's sera by lymphocytotoxicity and ELISA, and HLA class II by ELISA. One hundred class I ELISA-CM and 60 class II ELISA CM were performed. Expected CM results were determined positive or negative considering HLA typing of donor's cells and HLA-Ab specifi cities into recipient's sera. Agreements between expected CM results and observed ELISA-CM results were 93% for class I and 93.3% for class II. If expected CM results are considered as reference, results showed: ELISA class I-CM sensitivity 96.6%, specifi city 91.4%; ELISA class II-CM sensitivity 90%, specifi city 95%. On 32 sera without HLA class I-Ab, ELISA-CM were found positive for 2 sera belonging to patients developing class I-Ab one month later. One serum was found ELISA class I-CM negative whereas it was expected positive; other sera from the same recipient were found ELISA class I-CM positive. All sera without HLA class II-Ab were ELISA class II-CM negative. Organ specifi c anti-HLA class I and class II antibodies can be detected with this sensitive ELISA-CM assay. Anti-HLA antibodies identifi cation by specifi c and sensitive techniques and ELISA-CM assay are complementary methods for transplantation monitoring. We have tested this ELISA-CM assay by using packed frozen spleen cells. This source of donor's HLA antigens presents the advantage to give plenty material for the transplantation follow-up. While molecular techniques have enhanced the quality of HLA assignments, a down fall of certain techniques is the problem of ambiguous typings. With PCR-SSOP, ambiguous typings arise when the combination of two specifi cities have an identical typing pattern to two differing specifi cities, as a result of sequence homology. In such cases, additional PCR analysis, with primers to separate the combinations, is necessary for discrimination. An alternative approach employing combination probes has been adopted to solve this problem.
Haplotype-Specifi c Extraction, HSE, establishes haplotypes from individual samples by physically separating a diploid sample into its haploid components: Magnetic beads are selectively attached to polymorphic sites and used to isolate the targeted fragments of genomic DNA from a heterozygous mixture. We have used Haplotype-Specifi c Extraction / HaploPrep™ and TaqMan™ to further characterize MHChaplotypes based on seven SNP-markers located in a 100kb region of HLA-B and -C. Four families, each consisting of one proband and the two parents, have been typed and their haplotypes were derived based on diploid HLA-B, -C as well as seven polymorphic SNP sites using the ABI / Applera SNP primers. Independently, we haplo-separated the diploid samples based on known heterozygous sites at HLA-B or -C, as confi rmed by InnoLiPA typing. Furthermore, we established the SNP-haplotypes directly by TaqMan-typing the haploid samples. The results confi rmed the familybased haplotype structure. This demonstrates that HSE / HaploPrep™ and TaqMan™ can extend the analysis of MHC haplotypes to other HLA-linked genes and polymorphic markers such as micro-satellites and SNPs. This approach eventually may be useful to study disease association questions. HSE and TaqMan are scalable processes that work on single base mismatches and do not require signifi cant up front investments to carry out haplotype characterizations.
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COMBINATION PROBES -A SOLUTION FOR AMBIGUOUS HLA TYPING ASSIGNMENTS Fionnuala Williams, Ashley Meenagh, Derek Middleton
Histocompatibility & Immunogenetics Laboratory, City Hospital, Belfast, Northern Ireland While molecular techniques have enhanced the quality of HLA assignments, a down fall of certain techniques is the problem of ambiguous typings. With PCR-SSOP, ambiguous typings arise when the combination of two specifi cities have an identical typing pattern to two differing specifi cities, as a result of sequence homology. In such cases, additional PCR analysis, with primers to separate the combinations, is necessary for discrimination. An alternative approach employing combination probes has been adopted to solve this problem.
A combination probe is a specially constructed probe consisting of two separate probe sequences, which singly, are located in differing sites within the HLA sequence. The two sequences are joined by a small group of inert nucleotides to give a small separation between the two sequences. One example of use, applicable to HLA-DRB1 analysis, is the discrimination of the combination of HLA-DRB1*0101 with -DRB1*1301 from HLA-DRB1*0103 with -DRB1*1417, allele combinations with identical typing patterns following PCR-SSOP analysis. The combination probe, 5´ TCCTGGAGCAGAGGCGG-(TTTTT)-CGGGGTTGGT GAGAGCTT 3´, was designed to discriminate HLA-DRB1*0101 from the other alleles within this problem combination, thus providing a precise heterozygous result. In order for the probe to work effectively, hybridization of both sequences is necessary. In this particular case the two sequences present are separated by 32 nucleotides within the HLA-DRB1 exon 2 sequence. Similar probes have been used to resolve other ambiguous combinations within HLA-DRB1 assignments and for the discrimination of HLA-Cw*05 and -Cw*08 within HLA-C typing. The gain or loss of one or more individual chromosomes is referred to as aneuploidy and results in gene dose imbalances. Head and neck squamous cell carcinomas (HNSCC) are the sixth most common cancers in the developed world. At the time of diagnosis, 2/3 of these cancers are non-diploid resulting in poor prognosis. Evidence of aneuploidy in these tumors has been identifi ed at the chromosome level using techniques such as comparative genomic hybridization (CGH), fl uorescent in situ hybridization (FISH) and loss of heterozygosity (LOH). However, these techniques provide no gene information and are both diffi cult and laborious. As a result we have applied a technique known as multiplex amplifi able probe hybridisation (MAPH) to DNA extracted directly from tumor tissue. This novel approach enables the hybridisation of gene specifi c probes to genomic DNA that is quantitatively recovered and amplifi ed by PCR. Probes specifi c for 7 immune response genes, Y-and X-linked genes and a gene on chromosome 21 were developed and tested on healthy male and female controls, normal and tumor tissue. We showed that MAPH was able to reproducibly detect loss of gene copy number in both the healthy and tumor samples. Cell lines known to have chromosomal aberrations were also tested and confi rmed the ability of MAPH to detect loss and gain of genes. In samples from 15 HNSCC patients that contained more than 70% tumor cells, MAPH identifi ed tumors that showed; (i) no genes affected; (ii) few genes affected; (iii) many genes affected. Recently developed isothermal whole genome amplifi cation (WGA) using the Phi29 polymerase with random-sequence hexamer primers (GenomiPhi DNA Amplifi cation Kit, Amersham Biosciences) offers a means to prepare suffi cient DNA for required additional subsequent applications (e.g. requested retrospective HLA typing for IHWG -HSCT component etc.). This is especially required when disproportion between the need and the quantity of biological material of limited availability (blood, isolated DNA) appears. We tested the WGA product quality for HLA typing via PCR-SSP and SBT routinely performed in our laboratory. Material and methods: Altogether 13 samples of previously isolated (QIAGEN) DNA were amplifi ed utilizing the Phi29 polymerase (GenomiPhi). The quantity and quality of newly obtained DNA was measured spectrophotometrically. The DNA was used for HLA typing: PCR-SSP for HLA-A, B, DRB1 and SBT for HLA -DRB1 gene. Results: Median yield of DNA after WGA was 16.9mkg (12.6-39.9) that was 59-times (12-936x) more then the initial quantity. The quality was good enough to use the products for PCR-SSP HLA-A, B, DRB1 typing where the results matched the previous ones from original routinely (QIAGEN) isolated DNA. The SBT results of all samples agreed with PCR-SSP.
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We revealed the Phi29 polymerase-amplifi ed DNA is the good source of quality substrate for PCR-SSP and/or SBT HLA typing especially for HLA typing for donor registries if lack of initial biological material (blood, isolated DNA) occurs. The HLA region on the short arm of chromosome 6 is the most polymorphic region in the genome. For HLA-DPB1 106 alleles have been identifi ed based upon exon 2 polymorphism. HLA-DPB is not in linkage disequilibrium with any other HLA genes, explaining why DPB mismatches frequently occur in transplantations. On the other hand has it become evident that DPB1 matching is important in stem cell transplantation and second kidney transplantation. Exon 2 polymorphism is located in hypervariable regions 1-5 and alleles evolved through microgene conversion, recombination and mutations. It would be interesting to know how this exon 2 polymorphism extends to other parts of the molecule. Full length RNA analysis of the DPB1 gene provides the possibility to determine diversity of and evolutionary relationship between DPB1 alleles. A RT-PCR was set up to amplify exon 1 into the 3'UT region. Sequencing was performed using 4 sequence primers with Big Dye Terminator chemistry on an ABI 377 DNA sequencer. Full length sequences obtained were compared to the scarcely available sequences. Fifteen B-cell lines, covering the 11 most frequent DPB1 alleles, were tested. In addition to the exon 2 polymorphism, 22 polymorphic positions were observed: 8 in exon 3; 1 in exon 4; no polymorphism was found in exon 5 and 13 positions in exon 6. These polymorphic positions give rise to at least two main lineages. A non-synonymous substitution of methionine to leucine at codon 178 was observed in a cell line previously typed as DPB1*0402, giving rise to a new allele, DPB1*0402RG. A single nucleotide deletion was found directly after the TAA stop codon in the DPB1*1301 allele, which does not affect the protein. In conclusion, full length sequence polymorphism provides interesting features on DPB allele evolution which may affect the defi nition of allele groups. In view of the data obtained, this study will be extended to less frequent alleles. Sequence based typing (SBT) is the golden standard in HLA-typing. The most time consuming and error prone part of SBT is data-analysis. We improved our software package which now combines all sequences of one sample to a conclusive HLA-typing. This includes the assembly of sequences from different regions (e.g. exon 2 and 3 for class I), the heterozygous sequences as well as those obtained after allele separation (GSAP, GSSP) and, when available, sequences of additional regions (e.g. exon 4 and introns). All sequence information available will be used to its full extend. Independent of the equipment used, all sequences can be processed. The software also will guide through the typing process: in case of ambiguities, it will report which GSAP or GSSP reactions can be used to resolve the ambiguities. Analysis is highly automated: typings will be performed automatically; only when base calling cannot be determined with high reliability, the sequences have to be inspected manually. In case of uncertainties, multi-sequence analysis will assist in obtaining the correct base call, making use of the high reproducibility of sequence patterns, which are recognized by the software. The software package also contains export functions, which will create an xml output fi le, containing all relevant SBT information, including allele assignment and the sequences. These fi les can easily be used to import the data into local databases, for data exchange, and for direct submission of SBT data to the workshop. Haplotype-Specifi c Extraction, HSE, establishes haplotypes from individual patient's samples without knowledge of familial information by physically separating a diploid sample into its haploid components: Magnetic beads are selectively attached to polymorphic sites and used to isolate the targeted fragments of genomic DNA from a heterozygous mixture. Haplo-separated DNA is then analyzed with kits and assays in use for HLA-typing. In cases where very little DNA is available for a particular sample or where subsequent typing is problematic for other reasons, it can be desirable to generically amplify all available DNA fi rst. We have used the GenomiPhi™ kit (Amersham Biosciences) to amplify haplo-separated genomic DNA after HSE. The resulting amplifi ed DNA, when typed by sequence-specifi c oligonucleotide probes (SSOP; Innogenetics), is still haploid with essentially no visible residual component of non-targeted alleles, and the SSOP signal generated for a haplo-separated sample is considerably stronger than for a diploid control sample. This permits the unambiguous typing of potentially diffi cult diploid samples with allele pair combinations that fail to be resolved by conventional sequence-based typing (SBT) or SSOP. It should also permit the typing of haplo-separated samples with multiple polymorphisms over large linkage distances that may otherwise fail to amplify properly with locus-specifi c PCRs alone.
267
ASSIGN-SBT: NEW FEATURES FOR IMPROVED SBT ANALYSIS, MUTATION DETECTION AND SEQUENCE QUALITY ASSESSMENT David C Sayer and Damian M Goodridge. Conexio Genomics, Western Australia
The bottleneck to high throughput SBT is sequence analysis and allele assignment. In addition the issue of assessing and monitoring sequence quality and defi ning performance criteria have not been appropriately addressed. These issues are critical for maintaining throughput of high quality data, assessing new protocols and ensuring that quality is not compromised when key reagent batches are changed.
Assign-SBT is designed for high throughput SBT in clinical laboratories. Assign-SBT contains a unique suite of algorithms that combine speed and base call accuracy for high throughput SBT of highly polymorphic and complex systems that includes HLA. In addition, recently developed approaches to sequence electropherogram analysis enable improved accuracy of heterozygous base calls and mutation detection and quantitation. We have also created a novel algorithm for the assessment of sequence electropherogram quality that does not penalise heterozygous base calls. By combining the quality score at each position we are able to provide a quantitative assessment of sequence quality for each sample and each sequencing run.
In summary Assign-SBT is a complete package for laboratories wishing to use DNA sequencing for mutation detection and sequencing based typing of any gene.
Assign-SBT is user friendly, requires minimum training and can be used to analyse data from ABI, Amersham and Beckman sequencers and sequencing chemistry. In the past, the SBT method was not mono-allelic in many cases because the 2 alleles carried were not selectively amplifi ed. This method was based on allele or allele-group specifi c amplifi cation targeting polymorphisms located at the 5' or 3' ends of the DRB1 exon 2. Ambiguous results were obtained even after mono-allelic amplifi cation, due to the polymorphism located at the 5' end of exon 2 which was not studied. Therefore, we have developed a method to selectively amplify the 2 alleles of the complete exon 2 using allele (DRB1*01-intron1, DRB1*04-intron1, DRB1*07-intron1, DRB1*08-intron1 and DRB1*14-intron1) or allele-group (DRB1*15+16-intron1, DRB1*03+10+12-intron1, DRB1*03+11+13+14-intron1; DRB1*08+11+13-intron1 and DRB3-intron1) specifi c primers located in intron 1. Except the DRB1*11, *13 and DRB1*15, *16 allele combinations, for which the 2 alleles have to be selectively amplifi ed using a two step PCR, all the other allele combinations can be resolved using these intronic primers and the sequencing results obtained are immutable for exon 2. Preparation of ready-to-use aliquots of validated allele or allele-group PCR primer-mixes and pre-SBT PCR buffer makes the procedure very easy and saves a great deal of time.
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FLUORESCENT-BASED AUTOMATED FRAGMENT ANALYSIS OF STR POLYMORPHISM WITHIN TRANSMEMBRANE REGION OF THE MIC-A GENE IN CZECH POPULATION
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BENEFIT OF THE LUMINEX TEST IN ANTI HLA ANTIBODIES DETECTION AND IDENTIFICATION
Francoise DAUNY, Jacqueline DARRHORT, Jean Claude BENSA , Agnes MOINE, Dominique MASSON EFS Rhone Alpes, Site de Grenoble, France
The aims of this study were to evaluate the reliability in terms of sensibility, specifi city and practical application of the Labscreen test from One lamda dedicated to the detection and identifi cation of anti HLA class I and class II antibodies. Results : The test appeared to be easy to use, rapid and allows a simultaneous search of antibodies on 50 different samples The fi nal result given by the software has to be modifi ed manually, a positive result being assigned each time a single bead revealed to be positive. When an identifi cation test was processed on these light positive sera, no antibody could be identifi ed .These data suggest that a preliminary adjustment of the ratio should be done on each bead. Whith a corrected ratio, the concordance of results obtained by this technique and the Elisa Onelambda test can be estimated to 89% .The presence of antibodies in Luminex positive/ Elisa negative sera has been investigated and the results show that the characterised specifi city was always correlated to the patient history : antibodies directed against renal allograft or marital antigens, all these antibodies being previously identifi ed in these patients. These data suggest that the Luminex test shows higher sensitivity and specifi city, taking into account that the positive/negative ratio had been adjusted. A retrospective study will be done on patients transplanted with positive historical sera and negative current serum to detect possible hidden antibodies. An other application of such results could be to the identifi cation (and elimination) for a second graft ,of all the undesirable antigens (fi rst donor and/or marital ones) Advances in instrumentation and DNA sequencing chemistry have enabled SBT to become a common method for HLA typing. Until recently, a missing component for true high throughput SBT has been automated software analysis. Two critical functions that must be automated are allele typing and quality analysis. Simple allele typing that limits manual editing depends on having proper quality information. Measurements of quality are also essential for determining variation within and between data sets to identify sources of deviation in data quality; e.g. instrumentation, reagents, or operator error. Assign-SBT enables high throughput typing and QC analysis of sequencing data by measuring Quality Values (QV) for each base position in each sequence and providing the tools to analyze the QV scores with statistical outputs. In this study, we used Assign-SBT to perform high resolution typing of AlleleSEQR HLA-A, -B, -C, DRB1, DQB1, and DPB1 SBT reagents. As a validation process following a change from DYEnamic ET Terminators (Amersham) to BigDye Terminators (Applied Biosystems), we typed 96 DNA samples from the UCLA DNA Exchange. The panel represented a range of allele types and the data were analyzed for correct allele types, allele balance (i.e. drop-outs), and sequence quality (measured as signal strength and errors at constant positions). Assign-SBT calculated the mean and standard deviations of QV scores for each base position. A comparison of data from the two chemistries demonstrated correct typings with both. Using similar measures of data quality in a routine typing laboratory can help to increase throughput, improve data management, minimize systematic errors, and streamline overall quality control processes. In most of the cases PCR/SSP typing is used to identify HLA Class I HLA alleles and this technique has been shown to be very powerful Nethertheless, in some particular conditions mainly when an unusual SSP pattern is observed, a complementary strategy should be needed . In our lab we developped a monoallelic sequenced based typing method which allow us to resolve most of the PCR/SSP typing problems. Through our experience in the last three years, several examples found in our routine typing work have been chosen to illustrate different situations resulting in a defective PCR/SSP result. -Most of the the rare alleles differ from the common ones by a single mix with a reactivity pattern which has not been, most of the time, evaluated in the lab .The occurence of false positive or negative mixes observed through a systematic lab evaluation follow up for each kit, can defi nitively lead to an erroneous result.
274
USEFULNESS OF A SEQUENCE BASED TYPING STRATEGY IN
-For several samples, the PCR/SSP typing software will not be able to assign a result , the unusual reactivity pattern signing the presence of a new allele.Therefore, a complete sequence identifi cation is needed . -In some rare but existing cases, an ambiguity between two rare alleles is included in the fi nal result, because of the partial reactivity of the second allele. SBT typing is here the only valuable strategy to defi nitively identify the right allele.
In all these cases, the usefulness of the SBT strategy to identify rare or new alleles has been proven. The presence of a new HLA-A or B antigen was suspected in a patient suffering from an uveite after a particular pattern of reactivity using an in house lymphocytotoxicity technique with allosera. In fact, the A2 and B44 antigens were clearly identifi ed whereas the reactivity pattern of the B62 antigen highlighted a negative response with one of the fi ve specifi c allosera. On the other hand, strong reactions were observed with two A30+31 allosera when neither A30 nor A31 specifi c allosera reacted.
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HLA-A and B generic PCR-SSP typing confi rmed the presence of the A*02, B*15 and B*44 alleles.
Mono-allelic SBT of the B*15 allele highlighted a new B*15 allele, identical to the current B*15010101 allele except a point mutation at codon 56 leading to the replacement of the Glycine by an Arginine. The Glycine at amino acid position 56 is only found in the A30 and A31 antigens and seems to be suffi cient to create a specifi c epitope recognized by the two A30+31 allosera as well as by two A30+31 specifi c monoclonal antibodies of the commercial monoclonal typing tray set of "One Lambda". 
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IDENTIFICATION OF A 'NOVEL' ALLELE
